La Quaglia M P
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Chest Surg Clin N Am. 1998 Feb;8(1):77-95.
The survival rate of patients with osteogenic sarcoma has greatly improved with the institution of a multidisciplinary approach that combines multi-agent chemotherapy and limb-sparing surgery. Presently, 80% of those patients who do not have distant metastases at presentation will become long-term survivors, compared to 20% prior to 1970. For patients with metastases at diagnosis, or who develop metastases after initiation of treatment, long-term survival is also possible if all primary and metastatic disease is removed. The data presented in this article supports aggressive resection of pulmonary metastases in osteogenic sarcoma patients.
通过采用多学科方法,即联合多药化疗和保肢手术,骨肉瘤患者的生存率有了显著提高。目前,初诊时无远处转移的患者中,80% 将成为长期幸存者,而在1970年之前这一比例为20%。对于诊断时有转移或在治疗开始后出现转移的患者,如果所有原发性和转移性疾病都能被切除,也有可能实现长期生存。本文所呈现的数据支持对骨肉瘤患者的肺转移灶进行积极切除。